Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other EventsItem 8.01Other Events
Acorda Therapeutics, Inc. (the “Company”) previously reported a decision by the U.S. District Court for the District of Delaware, in connection with a lawsuit that the Company filed against certain generic drug manufacturers, upholding the Company’s Orange-Book listed patent for Ampyra set to expire on July 30, 2018 (United States Patent No. 5,540,938), but invalidating the Company’s four other Orange-Book-listed patents for Ampyra (United States Patent Nos. 8,007,826, 8,354,437, 8,440,703, and 8,663,685). In May 2017, the Company filed its planned appeal of the decision on the four invalidated patents with the United States Court of Appeals for the Federal Circuit. The Company is reporting that on June 7, 2017, defendants in the above-referenced lawsuit, Teva Pharmaceuticals USA, Inc., Roxane Laboratories, Inc., and Mylan Pharmaceuticals Inc., filed a cross-appeal to the United States Court of Appeals for the Federal Circuit with respect to District Court decision upholding United States Patent No. 5,540,938.
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine.